Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Molecular Health GmbH. (11/16/17). "Press Release: Molecular Health and U.S. Food and Drug Administration (FDA) Extend Software Collaboration to Drug Safety Prediction". Cambridge, MA.

Region Region United States (USA)
Organisations Organisation Molecular Health Inc.
  Group Molecular Health (Group)
  Organisation 2 FDA (US Food and Drug Administration)
  Group United States (govt)
Products Product software tools (bioinformatics)
  Product 2 pharmaceutical
Index term Index term United States (govt)–Molecular Health: drug safety software, 201711–202210 extension collab with CDER for additional 5 years
Persons Person von Bohlen, Friedrich (Dievini before Lion Bioscience)
  Person 2 Weß, Ludger (akampion before 2001–2006 BioCentury Senior Editor before Financial Times Deutschland)
     


Molecular Health, Inc (MH), a company marketing computational biomedicine tools to support healthcare decisions with clinical and molecular data, and the FDA's Center for Drug Evaluation and Research (CDER) have extended for an additional 5 years, their research collaboration to jointly address one of the biggest challenges in drug development: the prediction of drug safety. In recent years, nearly 30% of new drugs failed in Phase II and III clinical studies1 and 270 marketed drugs have been withdrawn worldwide for safety reasons2. To tackle this issue, MH has developed its Molecular Health Effect®(MH Effect) technology, a leading-edge software solution for the comprehensive clinical and molecular assessment of drug action and adverse events.

Under the initial research collaboration agreement (RCA) executed in January 2012, FDA used the MH Effect to molecularly analyze adverse events data. During the first five years of collaboration, MH Effect was used to evaluate the potential mechanisms of emerging safety issues. Under the new RCA, the FDA will continue to assess the ability of MH Effect to predict adverse events and safety label changes. The results of the collaboration will be incorporated into MH's technology to jointly advance computational capabilities for drug development.

"After our successful research collaboration with the FDA for the past 5 years, we are excited about the decision to extend our collaboration," said Dr. Friedrich von Bohlen, CEO of Molecular Health. " This decision underlines the unique value proposition of MH Effect for predicting and characterizing drug adverse events that patients are or can be exposed to. With MH Effect and our other products and technologies creating novel insights from data we will continue to help improve the development of novel medicines, with benefits for patients and the entire healthcare industry."


About Molecular Health

Molecular Health is a computational biomedicine company focused on big-data curation, integration and analytics to enable precision medicine. The company has developed Dataome®, a top quality-curated, interoperable technology system comprising a large set of databases and analytics that allow the integration and referencing of clinico-molecular drug and disease data to generate novel and actionable insights on drug outcomes for stakeholders across the healthcare ecosystem. These include physicians, hospitals, research networks, commercial labs, regulators and pharma companies. The company is compliant to all relevant regulatory certification and accreditation standards. Molecular Health's scientific and commercial teams are based in Heidelberg, Germany, and Boston, MA, USA.

To learn more, please visit: www.molecularhealth.com.


Contact Molecular Health

Scientific queries:
David Jackson
David.jackson@molecularhealth.com

Business queries to license the technology:
Blanca Baez
Blanca.baez@molecularhealth.com


Media Contact

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68


[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847363/

[2] http://cheminfo.charite.de/withdrawn/

   
Record changed: 2017-11-26

Advertisement

Picture [LSF] Life-Sciences-France.com – The Business Web Portal 600x80px

More documents for Molecular Health (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px